KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Interest & Investment Income (2017 - 2026)

Amneal Pharmaceuticals has reported Interest & Investment Income over the past 9 years, most recently at -$56.2 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 8.8% year-over-year to -$56.2 million; the TTM value through Dec 2025 reached -$241.1 million, up 6.77%, while the annual FY2025 figure was -$241.1 million, 6.77% up from the prior year.
  • Interest & Investment Income for Q4 2025 was -$56.2 million at Amneal Pharmaceuticals, up from -$62.8 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at -$33.3 million in Q1 2022 and troughed at -$65.7 million in Q2 2024.
  • A 5-year average of -$50.3 million and a median of -$50.9 million in 2023 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: increased 15.07% in 2021 and later crashed 47.94% in 2023.
  • Year by year, Interest & Investment Income stood at -$34.0 million in 2021, then crashed by 38.49% to -$47.0 million in 2022, then dropped by 26.62% to -$59.5 million in 2023, then fell by 3.55% to -$61.7 million in 2024, then grew by 8.8% to -$56.2 million in 2025.
  • Business Quant data shows Interest & Investment Income for AMRX at -$56.2 million in Q4 2025, -$62.8 million in Q3 2025, and -$65.1 million in Q2 2025.